Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 21 Genitourinary 10 Breast 10 Gynecologic 6 Plasma cell 5 Thoracic 3 Lymphoid 3 Other hematologic neoplasm 2 Tumor-Agnostic 1 Other 1 Myeloid 1 Head & Neck 1 Dermatologic 1 CNS 1

Conditions

Neurofibromatosis 1 1

Interventions

Temozolomide 623 Radiotherapy 410 Bevacizumab 256 Magnetic Resonance Spectroscopy 226 Cyclophosphamide 179 Radiosurgery 162 Carboplatin 160 Etoposide 132 Radiation 128 Vincristine 115 Irinotecan 115 Cisplatin 103 Filgrastim 100 Specimen Handling 90 Nivolumab 88 pembrolizumab 83 Surgical Procedures, Operative 83 Lomustine 82 Topotecan 73 Doxorubicin 61 Melphalan 59 Carmustine 57 Radiotherapy, Intensity-Modulated 56 sargramostim 53 Isotretinoin 53 Peripheral Blood Stem Cell Transplantation 52 Granulocyte Colony-Stimulating Factor 51 Chemotherapy, Adjuvant 51 Blood Specimen Collection 51 Erlotinib Hydrochloride 50

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Curcumin × CNS × Clear all

NCT05363267 2026-01-13

NF-1, Nutraceutical Intervention

Masonic Cancer Center, University of Minnesota

Phase 1 Active not recruiting

Neurofibromatosis 1

Data powered by HemOnc (CC BY 4.0) Colophon ⚡